Biomarkers in Autoimmune Disease of Nervous System

Launched by TONGJI HOSPITAL · Jul 13, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at different autoimmune diseases that can affect the nervous system, such as Multiple Sclerosis, Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder. These conditions happen when the immune system mistakenly attacks parts of the nervous system, leading to various symptoms and making diagnosis and treatment difficult. The researchers aim to find specific biological markers, or "biomarkers," that can help doctors diagnose these diseases earlier, monitor their progress, and tailor treatments to individual patients. This could ultimately improve the quality of life for those living with these conditions.

To participate in this trial, individuals between certain ages who have been clinically diagnosed with one of the targeted autoimmune diseases may be eligible. Healthy individuals of the same age and sex may also take part in the study. Participants can expect to undergo assessments to help identify the biomarkers being researched. It's important to note that certain individuals with specific health issues, such as severe infections or other serious medical conditions, will not be eligible to join the study. This research is crucial as it could lead to better understanding and management of these challenging diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al.
• • sex and age-matched healthy individuals
• Exclusion Criteria:
• • Known history of primary immunodeficiency (innate or acquired).
• • Patients with severe central nervous system, pulmonary, or other systemic infections.
• • Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome.
• • Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases.
• • Pregnant or lactating women.